PL4125802T3 - 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc - Google Patents

5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc

Info

Publication number
PL4125802T3
PL4125802T3 PL21714312.2T PL21714312T PL4125802T3 PL 4125802 T3 PL4125802 T3 PL 4125802T3 PL 21714312 T PL21714312 T PL 21714312T PL 4125802 T3 PL4125802 T3 PL 4125802T3
Authority
PL
Poland
Prior art keywords
phthalazinedione
dihydro
amino
treatment
lung injury
Prior art date
Application number
PL21714312.2T
Other languages
English (en)
Inventor
Wolfgang Brysch
Astrid Kaiser
Petra Schulz
Sara SCHUMANN
Jörg VON WEGERER
Christian SETZ
Ulrich Schubert
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of PL4125802T3 publication Critical patent/PL4125802T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL21714312.2T 2020-03-25 2021-03-24 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc PL4125802T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20000133 2020-03-25
PCT/EP2021/000028 WO2021190783A1 (en) 2020-03-25 2021-03-24 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury

Publications (1)

Publication Number Publication Date
PL4125802T3 true PL4125802T3 (pl) 2026-03-23

Family

ID=70049815

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21714312.2T PL4125802T3 (pl) 2020-03-25 2021-03-24 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc

Country Status (12)

Country Link
US (1) US20230113516A1 (pl)
EP (1) EP4125802B1 (pl)
JP (1) JP7844340B2 (pl)
KR (1) KR20220158030A (pl)
CN (1) CN115768402A (pl)
AU (1) AU2021244864B2 (pl)
BR (1) BR112022019141A2 (pl)
CA (1) CA3168777A1 (pl)
ES (1) ES3057259T3 (pl)
IL (1) IL296058A (pl)
PL (1) PL4125802T3 (pl)
WO (1) WO2021190783A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3981405A1 (en) * 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
AU2021288757B2 (en) * 2020-06-10 2026-01-08 Metriopharm Ag Compound for the treatment of coronaviral infections
US20240075029A1 (en) * 2020-12-02 2024-03-07 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
EP4193994A1 (en) * 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
EP4209219A1 (en) * 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
EP4784132A1 (en) * 2023-09-26 2026-08-05 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953799B1 (en) 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US7582297B2 (en) * 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
US8895555B2 (en) * 2009-02-19 2014-11-25 Bach Pharma, Inc. Methods of treating intestinal diseases and inflammatory conditions related to HIV-AIDS
PT2542535E (pt) * 2010-03-01 2014-08-25 Metriopharm Ag Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas
EP2688565A1 (en) 2011-03-23 2014-01-29 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
JP2017537958A (ja) * 2014-12-18 2017-12-21 メトリオファーム アーゲー ５−アミノ−２，３−ジヒドロフタラジン１，４−ジオンナトリウム塩の結晶形態、同一物を含む医薬製剤、及びこの形態の製造ための方法
WO2017140422A1 (en) * 2016-02-16 2017-08-24 Metriopharm Ag Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
CN109563052A (zh) * 2016-02-16 2019-04-02 麦翠奥制药公司 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体
EP3248602A1 (en) 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
DK3534904T3 (da) 2016-11-07 2022-04-11 Metriopharm Ag Anvendelse af 5-amino-2,3-dihydro-1,4-phthalazindion i behandlingen af kronisk progressiv multipel sklerose
EP3511325A1 (en) 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione

Also Published As

Publication number Publication date
IL296058A (en) 2022-10-01
EP4125802A1 (en) 2023-02-08
JP2023519526A (ja) 2023-05-11
ES3057259T3 (en) 2026-02-27
AU2021244864A1 (en) 2022-09-22
KR20220158030A (ko) 2022-11-29
EP4125802B1 (en) 2025-10-01
WO2021190783A1 (en) 2021-09-30
AU2021244864B2 (en) 2025-12-18
CA3168777A1 (en) 2021-09-30
US20230113516A1 (en) 2023-04-13
JP7844340B2 (ja) 2026-04-13
CN115768402A (zh) 2023-03-07
BR112022019141A2 (pt) 2023-01-17
EP4125802C0 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
EP4125802C0 (en) 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZIN IONES FOR THE TREATMENT OF ACUTE LUNG INJURIES
PL4164651T3 (pl) 5-amino-2,3-dihydro-1,4-ftalazinedion do stosowania w leczeniu zakażeń koronawirusowych
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
IL308698A (en) Tissue treatment system
ZA202109003B (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
HUE071698T2 (hu) Glükokortikoid-csökkentõ szer
BR112012018960A2 (pt) ligante sigma, utilização do mesmo e método de tratamento de um paciente sofrendo de dor desenvolvida em consequência de cirurgia, ou propenso a sofrer dor como resultado de tratamento cirúrgico
EP3930740A4 (en) METHODS, COMPOSITIONS, FILMS FOR THERAPEUTIC SKIN TREATMENTS
PL3737668T3 (pl) Sposób solubilizacji 5-amino-2,3-dihydro-1,4-ftalazynodionu
EP4096628C0 (en) USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE INHALATION TREATMENT OF INFLAMMATORY PULMONARY DISEASES
EP3816285A4 (en) DOUBLE-STRANDED OLIGONUCLEOTIDE SPECIFIC TO THE AMPHIREGULIN GENE AND COMPOSITION, FOR THE PREVENTION AND TREATMENT OF FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, INCLUDING THE SAME
GB202205698D0 (en) Medical treatment devie and method of operation thereof
EP3492026A3 (en) Surgical reamer for removing bone
EP4069251A4 (en) SALTS AND POLYMORPHS OF CETHROMYCIN FOR THE TREATMENT OF DISEASES
EP3836953A4 (en) Compositions and methods for treatment of acute lung injury
EP3982999A4 (en) COMPOSITION AND METHODS OF TREATMENT OF LIVER TISSUE DAMAGE
GEP20207136B (en) Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition
EP4387622C0 (en) HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY
AU2022242765A1 (en) Combined treatment of brain injury
GB202304661D0 (en) New compounds and medical uses thereof
GB202304652D0 (en) New compounds and medical uses thereof
EP4241722C0 (en) DENTAL BURRS FOR ANATOMY AND REDUCTION OF ANESTHETIC USE
GB2595502B (en) Compounds, compositions and methods for the treatment or prevention of hair loss
GB202008250D0 (en) Diagnosis, prevention and treatment of coronavirus infection
ZA202007597B (en) Method for determining treatment of orthopaedic imbalances, and apparatus therefor